Aummune

Aummune is at the forefront of biotechnology research, pioneering the future of personalized cancer therapy. Aummune is dedicated to developing a groundbreaking drug-customization platform, unlike any other in the industry. This innovative approach employs a unique efficacy-driven selection process to match and produce patient-specific, tri-functional aptamer drugs. These drugs are designed to safely and synergistically induce cancer cell death while activating both innate and adaptive immune responses.

Aummune's commitment to individualized medicine sets it apart, ensuring that each patient receives a treatment plan tailored to their unique needs. Located primarily at Weizmann 6, Tel Aviv-Yafo, IL, and with an additional location at Hamarpe 2, Jerusalem, IL, Aummune is strategically positioned to advance its research and development efforts. The company's innovative platform holds immense promise for transforming cancer treatment and improving patient outcomes.

Aummune is poised to revolutionize the landscape of cancer therapy through its cutting-edge research and personalized approach. Aummune is committed to pushing the boundaries of biotechnology to deliver safer, more effective treatments to patients worldwide. We invite the manager of Aummune to create a customized and exclusive company showcase and product listing on our platform to further enhance its visibility and commercial development.